Media Releases

A Decade Later Human Genome Discoveries Spur Growth of Cancer Treatments

August  24, 2010 - 

Columbus, Ohio (August 24, 2010) Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information.

Since President Clinton announced that the draft sequence of the human genome was completed in 2000, research about specific types of cancers grew exponentially. Fifty years of cancer and Chronic Myelogenous Leukemia (CML) drug treatments are examined in the CAS Chemistry Research Report: Human Genome Discoveries Spur Growth of Cancer Treatments. CAS researchers confirmed that Gleevec succeeded as a first-generation drug that targeted CML, as originally reported by Novartis and Oregon Health and Science researchers. Second- and third-generation CML-targeted drugs benefited from Gleevec's patent success and continued to propel the growth of CML research and patent publications.

Other important findings from the CAS report include:

  • During the last 20 years, cancer therapy journal publications grew 179 percent, while patent publications grew 318 percent.
  • From 1990 to 2009, journal article publications about CML treatment expanded 196 percent. At the same time, patent publications exploded with 700 percent growth.
  • The World Intellectual Patent Organization (WIPO) is the leading patent authority for Gleevec use in CML.
  • U.S. researchers authored three times as many journal publications for Gleevec as any other country.
  • In 2009, second-generation drugs Tasigna and Sprycel displaced Gleevec as single medications for CML, with a combined 41-fold increase in journal publications and a concomitant increase in patent publications compared to Gleevec.

"The results of the analysis outlined in the CAS Chemistry Research Report further validate that we are on the right course. The accelerated growth in CML-related publications following Gleevec provides yet more evidence that the targeting approach opened up new paths of exploration for the medical and scientific communities. Based on this success we are now optimistic that all cancers could be controlled with drugs like Gleevec," Dr. Brian Druker, Director, Oregon Health

 

About CAS

Chemical Abstracts Service (CAS), a division of the American Chemical Society, is the world's authority for chemical information. CAS is the only organization in the world whose objective is to find, collect and organize all publicly disclosed substance information. A team of scientists worldwide curates and controls the quality of our databases, which are recognized as the most comprehensive and authoritative by chemical and pharmaceutical companies, universities, government organizations and patent offices around the world. By combining these databases with advanced search and analysis technologies (SciFinder® and STN®), CAS delivers the most current, complete, secure and interlinked digital information environment for scientific discovery.


About CAS Chemistry Research Reports

The CAS Chemistry Research Report series examines journal and patent publication records to identify global trends in scientific research and its commercialization. The reports are developed by CAS scientists and other researchers, who analyze decades of data represented in CAS databases, the largest and most authoritative databases of scientific information.

 Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624                                       
 Email: cas-pr@cas.org